Hers Labs is best when you want women's-health-oriented preventive labs drawn at a Quest location with telehealth review and a guided plan. AMORTAL is different — it isn't a lab company. It takes whatever results you already have and builds a longitudinal trail: one ranked next action, a watchlist, a clinician-ready question, and a loop that checks whether the action worked.
Hers built a women’s-health lab experience that’s easy to act on: book a blood draw at a Quest location, get a panel oriented around women’s preventive and lifestyle-linked health, have results reviewed by telehealth providers, and step into a guided plan inside the app. It answers “what do my numbers look like, and what’s the next pathway?” smoothly.
What it’s not built to be is a neutral, longitudinal memory across every provider you’ll ever use. Hers is a treatment-linked platform — its action plans point back into its own pathways. That’s the gap this page is about: where AMORTAL fits as the decision and memory layer that keeps your lab history portable, vendor-neutral, and tied to one ranked next step. It’s educational, not medical advice.
+
Use Hers for the women's-health lab data. Use AMORTAL to decide what the data should change, what to ignore, what to watch, and when to retest.
The short version: who each is for
These two aren’t really competitors — one produces the data and the guided plan, the other decides what to do with the data across every provider. Here’s the honest split.
Which one fits which job
Hers LabsBest for women's preventive lab plansWomen's-health-oriented biomarker panels drawn at Quest locations, reviewed by telehealth providers and tied to a guided plan inside the app. Strongest when you want preventive, lifestyle-linked labs and telehealth in one place.
AMORTALBest for deciding what to do nextNot a lab. A longitudinal decision layer that reads whatever results you already have — from Hers or anywhere — and returns one ranked next action, a watchlist, a clinician-ready question, and an outcome loop. Including when to do nothing.
This isn't an "A beats B." Hers answers what are my numbers, and what's the guided plan; AMORTAL answers what should they change across every provider. The strongest setup uses both.
Hers Labs vs AMORTAL, at a glance
Tap between the two to see what each is actually responsible for.
What each one owns
Same goal — better decisions from your blood — split into the data job and the decision job.
The women's-health lab layer
Hers runs women's-health-oriented panels drawn at Quest locations — Hers advertises a choice of 2,000+ Quest sites and panels in the 75+ biomarker range, with some FAQ copy citing 130+ (verify current) — reviewed by telehealth providers and tied to in-app guidance.
You want preventive, lifestyle-linked women's-health labs plus telehealth in one place, and a guided plan to follow. Verify the current panel scope, price and Quest network on Hers's own pages before you buy.
The decision layer
AMORTAL doesn't draw blood. It takes your Hers results (or any lab's), normalises them into a memory, and produces one ranked next action, a watchlist, a clinician-ready question, and an outcome loop — with restraint built in.
You already have results and the real question is "what now?" — what to change, what to ignore, what to watch, and when a retest is actually worth it.
AMORTAL has no direct Hers or Quest integration — you bring the data in by upload or manual entry.
The comparison, row by row
| Dimension | Hers Labs | AMORTAL |
|---|---|---|
| Best use case | Women’s-health preventive lab plan | Deciding what the data should change |
| Collection method | Blood draw at Quest locations (as advertised) | No draws — works from results you already have |
| Lab partner / processing | Processed by Quest (as advertised) | Lab-agnostic; vendor-neutral by design |
| Biomarker breadth | Hers advertises panels in the 75+ range, with some FAQ copy citing 130+ (verify current) | Doesn’t test; reads whatever you bring |
| Upload existing labs | Lives within the Hers app | Yes — bring Hers or any other results in |
| Wearable integration | Not the core product | Connects labs to Oura / Whoop / Apple Watch context |
| Clinician review | Telehealth providers (as advertised) | Clinician-compatible questions; not a clinician |
| Action plan depth | App guidance / treatment pathways (as advertised) | One ranked next best action, plus restraint |
| Retesting cadence | Per Hers’s plan | Tells you when not to retest yet |
| Result trend tracking | Trends within the Hers app | Longitudinal memory across providers and time |
| Abnormal-result handling | Reviewed by Hers’s providers (as advertised) | Safety-gated; routes urgent flags to a clinician, never diagnoses |
| Data portability | Your results live in Hers | Cross-provider memory you carry with you |
| Cost model | Via Hers (verify current) | Decision layer — founding membership |
| Where AMORTAL fits | Women’s-health labs in | → ranked decision, watchlist, and outcome loop out |
Provider rows describe what Hers publicly advertises as of June 2026 — panel scope, pricing and the Quest network change often, and Hers's own pages list different biomarker counts in different places, so confirm the current details on Hers's pages before buying. Sources are listed at the foot of this page.
Which one fits what you actually want
| What you want | Reach for |
|---|---|
| Women’s-health-oriented labs plus telehealth in one place | Hers Labs |
| A guided preventive plan to follow | Hers Labs |
| I already have results — tell me what to do next | AMORTAL |
| To build a longitudinal trail across providers | AMORTAL |
| A clinician-ready question, not a treatment directive | AMORTAL |
| To know whether a protocol actually worked | AMORTAL (then retest via Hers) |
| To avoid changing five things at once | AMORTAL |
| To know whether I should retest yet | AMORTAL |
How AMORTAL complements Hers Labs
The model is simple: let Hers do the testing and telehealth it does well, then run the result through a decision process instead of a single-app dashboard.
- Bring the result in. Upload your Hers panel or enter the key markers — there's no direct integration, so you carry the data over.
- Normalise into memory. AMORTAL files each biomarker into a longitudinal record, not a one-off screen.
- Connect the context. Results are linked to your goals, symptoms, wearables, medications and constraints.
- Activate the standards. The guidelines and decision rules that actually apply to your situation switch on.
- Produce a Decision Contract. One change at a time, with the expected signal and the window written down in advance.
- Rank one Next Best Action. Not ten. The single highest-value move — which may be "do nothing yet."
- Set the watchlist. Markers worth re-checking get an expected direction and a recheck window.
- Close the loop. When the next Hers panel or outcome signal arrives, AMORTAL checks whether the action worked — and keeps or discards it.
A decision loop, end to end
Here’s the same flow on a single example — illustrative only, not a target or a reference range.
From a Hers result to a tracked outcome
Your Hers panel returns a low ferritin (say, in a range your clinician flags as worth attention). In a treatment-linked app, that's a flag and a nudge toward a pathway.
AMORTAL files it next to your prior iron studies, your goals, your cycle and symptom notes, your medications and your wearable trends — so it's read as a trajectory, not a single dot.
One lever, not five. The expected signal (ferritin direction) and the window to see it are written down before anything changes.
Framed as a clinician-ready question — "given this trend, is [one specific lever] the right first move?" — not a treatment directive AMORTAL has no authority to give.
The marker goes on watch with an expected direction and a recheck window — so you retest when it's informative, not on a guess.
At the next draw, AMORTAL checks: did it move as expected? If yes, the change earns its place. If not, it's dropped — no story told over noise.
AMORTAL doesn't diagnose and isn't a substitute for your clinician — anything urgent goes to a professional, now.
Is your lab data building a longitudinal trail?
More data isn’t a memory. Three quick checks tell you whether your lab results are compounding into a trail you can decide from — or just piling up as snapshots.
Is your lab data building a longitudinal trail?
Tick what's genuinely true today. Two of three is a real longitudinal habit.
Tick what's true above
Your read on your lab data appears here.
A guide, not a guarantee. A trail is only useful if the next decision reads from it — which is exactly the loop AMORTAL is built to keep.
Where Hers is strongest — and where it isn’t
In fairness to both tools:
- Hers is strongest when you want women’s-health-oriented preventive labs, drawn conveniently at a Quest location and reviewed by telehealth providers, with a guided plan to follow.
- Hers may be less ideal if you want a vendor-neutral record across every provider, or your real bottleneck isn’t getting data but deciding on the data you already have.
- Verify before you buy. Panel scope, price and the Quest network change — and Hers lists different biomarker counts in different places (75+ in some copy, 130+ in others), so confirm the current details on Hers’s own pages.
- A panel is a beginning, not an answer. Some results will need a clinician; AMORTAL should never be read as a diagnosis, and anything urgent goes to a professional now.
Bring your results into a decision, not a dashboard
AMORTAL doesn’t need to be where you buy every blood test. The stronger model is to let a focused provider like Hers run the women’s-health labs it does well, then use AMORTAL as the longitudinal decision system around those results — portable across every provider, not locked to one app. Upload a Hers panel, or enter the markers that matter. AMORTAL turns the result into memory, evaluates what’s still missing, ranks the next best action, sets a watchlist for the signals to expect, and later checks whether the action actually worked.
Already have results from Hers? Bring them into AMORTAL and ask: “What should I do next?”
Sources
Provider claims describe what Hers publicly advertised when this page was last fact-checked (26 June 2026). Panel scope, pricing and the Quest network are volatile — and Hers’s own pages cite different biomarker counts — so verify on the official pages before purchase.
Hers Labs — frequently asked questions, including panel detail and the biomarker counts processed by Quest.
Hers Labs — how it works, including the Quest-location draw and the advertised biomarker range.
Educational only — this is not medical advice or a diagnosis. Talk to a licensed clinician about your own numbers, targets, and any treatment decisions.
Frequently asked
Can I use AMORTAL with my Hers results?
Yes — that's the intended use. Hers gives you a women's-health-oriented panel drawn at a Quest location; you bring those results into AMORTAL by uploading the report or entering the key markers. AMORTAL normalises them into a longitudinal memory, connects them to your goals, cycle, wearables and any protocols, and returns one ranked next action rather than a wall of numbers. AMORTAL has no direct Hers or Quest integration; you bring the data in.
Does AMORTAL replace Hers?
No. They do different jobs. Hers is a data source plus telehealth — it runs the women's-health panel through Quest and points you toward its own guided plan. AMORTAL is a vendor-neutral decision layer that sits on top of whatever lab data you have. Most people who use both keep Hers for the convenient, preventive panel and use AMORTAL to decide what each result should change, what to ignore, and when to retest.
Does AMORTAL order the test for me?
No. AMORTAL is not a lab or a telehealth service and does not order or sell tests. It works from results you already have — from Hers, a clinician, or any other lab. If a decision genuinely needs a test you don't have yet, AMORTAL will say so and tell you which one would actually change the decision, rather than encouraging you to test everything.
What does AMORTAL do after my Hers results come in?
It files them into your health memory, activates the standards that apply to you, and produces a Decision Contract: one next best action, the single signal you'd expect it to move, and the window to watch. It also creates watchlist items for markers worth re-checking later — and, importantly, will tell you when the right move is to change nothing yet.
Is a bigger biomarker panel always better?
Not automatically. A women's-health panel like Hers's is genuinely useful for a preventive baseline, but more markers also mean more borderline results that tempt over-reaction — and Hers itself advertises different counts in different places. AMORTAL evaluates whether a marker actually changes a realistic decision, whether the result is timely, whether a clinician should weigh in, and what downstream signal to watch — so breadth becomes useful instead of noisy.
Why do Hers's advertised biomarker counts differ (75+ vs 130+)?
Because marketing copy and FAQ pages can describe different panel scopes, and these change often. Hers's how-it-works copy cites testing up to 75+ biomarkers in one appointment, while some FAQ copy mentions panels processed by Quest with 130+ biomarker tests. Treat neither as definitive — verify the current panel on Hers's own pages before buying. AMORTAL works from whatever markers you actually receive, regardless of the headline count.